BERLIN (Reuters) – German biotech firm CureVac has agreed to an alliance with drugmaker Bayer to get global support in seeking approval for its experimental COVID-19 vaccine and for distribution, the two companies said on Thursday.
“Bayer will contribute its expertise and established infrastructure in areas such as clinical operations, regulatory affairs, pharmacovigilance, medical information, supply chain performance as well as support in selected countries,” they said.
Financial terms were not disclosed.
(Reporting by Kirsti Knolle and Ludwig Burger; editing by Thomas Seythal)
